4974
TAKARA BIO INC.
タカラバイオ
- Industry
- Chemicals
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
46,086
Mar 2022
67,699
Mar 2023
78,142
Mar 2024
43,505
Mar 2025
45,039
Operating profit(million JPY)
Mar 2021
13,952
Mar 2022
28,902
Mar 2023
20,541
Mar 2024
3,003
Mar 2025
2,263
Operating profit margin(%)
Mar 2021
30.27
Mar 2022
42.69
Mar 2023
26.29
Mar 2024
6.9
Mar 2025
5.02
Profit before tax(million JPY)
Mar 2021
13,552
Mar 2022
27,532
Mar 2023
21,224
Mar 2024
2,853
Mar 2025
1,997
Profit(million JPY)
Mar 2021
9,547
Mar 2022
19,849
Mar 2023
16,012
Mar 2024
1,480
Mar 2025
1,041
Total assets(million JPY)
Mar 2021
89,750
Mar 2022
115,712
Mar 2023
129,202
Mar 2024
121,252
Mar 2025
125,334
Cash and cash equivalents(million JPY)
Mar 2021
23,308
Mar 2022
22,160
Mar 2023
49,058
Mar 2024
33,171
Mar 2025
27,036
Cash flows from operating activities(million JPY)
Mar 2021
13,943
Mar 2022
6,985
Mar 2023
36,897
Mar 2024
1,711
Mar 2025
5,844
Cash flows from investing activities(million JPY)
Mar 2021
-3,778
Mar 2022
-7,071
Mar 2023
-6,693
Mar 2024
-13,043
Mar 2025
-10,912
Cash flows from financing activities(million JPY)
Mar 2021
-1,103
Mar 2022
-2,070
Mar 2023
-4,119
Mar 2024
-5,233
Mar 2025
-2,256
Return on equity(%)
Mar 2021
13.57
Mar 2022
23.35
Mar 2023
15.39
Mar 2024
1.32
Mar 2025
0.92
Equity ratio(%)
Mar 2021
82.7
Mar 2022
82.9
Mar 2023
86.9
Mar 2024
92
Mar 2025
92.2
Earnings per share(JPY per share)
Mar 2021
79.29
Mar 2022
164.84
Mar 2023
132.97
Mar 2024
12.3
Mar 2025
8.65
Net assets per share(JPY per share)
Mar 2021
616.05
Mar 2022
796.18
Mar 2023
931.93
Mar 2024
926
Mar 2025
959.19
Dividend per share(JPY per share)
Mar 2021
16
Mar 2022
33
Mar 2023
42
Mar 2024
17
Mar 2025
17
Payout ratio(%)
Mar 2021
20.18
Mar 2022
20.02
Mar 2023
31.59
Mar 2024
138.21
Mar 2025
196.53
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.